Q-omics provides the consensus-scored NLGN4Y profile across patient tissues and cancer cell-line models. NLGN4Y expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NLGN4Y is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, NLGN4Y RNA expression shows 9,524 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRP, and TGCT as cancer lineages where NLGN4Y shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLGN4Y — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLGN4Y survival associations across molecular data types. NLGN4Y RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLGN4Y RNA expression–survival associations across cancer types. High NLGN4Y expression shows unfavorable associations in THCA and SCLC, but favorable associations in HNSC, KIRC, LUAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NLGN4Y RNA expression.
This table summarizes NLGN4Y tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NLGN4Y. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLGN4Y shows lower tumor expression in KIRP, KICH, BLCA, PRAD and STAD and higher tumor expression in CHOL. The KIRP box plot shows higher NLGN4Y RNA expression in normal versus tumor tissue (log2 FC = −1.083, t-test p < 0.001).
This table shows molecular features associated with NLGN4Y in patient tissues and cancer cell lines. In patient samples, NLGN4Y shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NLGN4Y RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
